Trial Profile
A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Levonorgestrel (Primary) ; Metformin; Progesterone congeners
- Indications Adenocarcinoma; Endometrial cancer; Endometrial hyperplasia
- Focus Therapeutic Use
- Acronyms feMMe
- 13 Apr 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 30 Mar 2021 Protocol was amended for reasons like; some patients were taking M already; others were ineligible for the WL intervention; and some young women who desired fertility did not meet the criteria because their BMI was lower than the required 30 kg/m2. So that patients who were ineligible for one of the three arms could still be enrolled.
- 30 Mar 2021 Results published in the Gynecologic Oncology